The ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, published by the Allergy Immunology Society of Thailand, is a pivotal platform for disseminating high-quality research in the fields of allergy and immunology. Established in 1983, this journal has consistently evolved to address the pressing challenges and advancements in these dynamic disciplines, contributing significantly to the global scientific community's understanding of immunological disorders. With a category ranking of Q3 in Immunology and Allergy, and Q2 in Medicine (miscellaneous) for 2023, the journal stands at the forefront of impactful research, engaging with a diverse audience of researchers, clinicians, and students alike. Although it operates on a non-open access model, its rigorous peer-review process ensures that published articles meet the highest academic standards. Located in Bangkok, Thailand, the journal connects researchers across the Asia-Pacific region, fostering collaboration and innovation to enhance patient care in the realm of allergy and immunology.

Welcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.

Endocrine Metabolic & Immune Disorders-Drug Targets, published by Bentham Science Publishers, is a premier journal focused on the intricate interplay between endocrinology, metabolism, and immune response, with a particular emphasis on drug targets. Established in 2006 and set to continue its influence until 2024, this journal serves as a crucial platform for researchers and professionals to communicate significant advances in understanding metabolic and immune disorders, making it an invaluable resource in the realms of Endocrinology and Immunology. With an impact factor positioned within the Q3 category for both Endocrinology, Diabetes and Metabolism, and Immunology and Allergy as of 2023, the journal stands at the crossroads of critical research and clinical application, facilitating ongoing dialogue among the scientific community. Although currently not open access, its dedication to high-quality peer-reviewed articles ensures that cutting-edge research remains accessible to those invested in enhancing therapeutic strategies. For researchers and practitioners alike, Endocrine Metabolic & Immune Disorders-Drug Targets is an essential conduit for the latest findings that can influence treatment paradigms and bolster the understanding of complex biological systems.

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

CRITICAL REVIEWS IN IMMUNOLOGY, published by BEGELL HOUSE INC, is an essential journal in the field of immunology that has been contributing to the scientific discourse since 1980. With its ISSN 1040-8401 and E-ISSN 2162-6472, this journal provides a platform for critical analysis and comprehensive reviews that deepen understanding of immune responses and their implications in health and disease. Although currently categorized in the Q4 quartile for Immunology and Q3 for Immunology and Allergy, the journal's quality research and scholarly contributions are crucial for advancing knowledge within its fields—encompassing various aspects of innate and adaptive immunity. Researchers and professionals in immunology will find invaluable insights, aiding them in their quest for innovation and excellence, as the journal aims to foster interdisciplinary collaboration. While it does not operate on an open-access model, CRITICAL REVIEWS IN IMMUNOLOGY remains a significant resource for those dedicated to pushing the boundaries of immunology, with annual publications expected to last well into 2024 and beyond.

Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.

Journal of Immunology Research, published by HINDAWI LTD, stands as a pivotal open-access journal in the realm of immunology, with a particular emphasis on advancing knowledge in both fundamental and applied aspects of the field. Since its inception in 1990, the journal has committed to the dissemination of high-quality research, earning a respectable impact factor that reflects its significance. Based in Egypt, it provides a platform for researchers from around the world, showcasing innovative studies and reviews that contribute to the understanding of immune system mechanisms. Its 2023 rankings place it in the Q2 category for Immunology and Allergy, and Q1 in the broader category of Medicine (miscellaneous), indicating a strong reputation among its peers. Through its open-access model, the journal promotes wide accessibility of cutting-edge research, catering to researchers, professionals, and students alike. With ambitions that converge through 2024, the Journal of Immunology Research continues to be an essential resource for those seeking to explore the forefront of immunological science.

The Scandinavian Journal of Rheumatology, published by Taylor & Francis Ltd, is a prestigious peer-reviewed journal dedicated to advancing research in the fields of rheumatology, immunology, and related disciplines. With an ISSN of 0300-9742 and an E-ISSN of 1502-7732, this journal has established itself as a vital platform for disseminating significant findings and innovative approaches in the management of rheumatic diseases since its inception in 1959. As a recognized scholarly outlet, it currently resides within the Q2 category for Medicine (miscellaneous) and ranks #39 out of 73 in Rheumatology according to the 2023 Scopus assessments. This reflects the journal's commitment to high-quality research and its relevance in the scientific community. Although it does not provide Open Access options, the journal's rigorous selection process ensures that only the most impactful research reaches its audience, making it a crucial resource for researchers, clinicians, and students engaged in the exploration of rheumatological and immunological challenges. The journal's broad scope encompasses ongoing studies, clinical trials, and reviews that aim to enhance understanding and treatment of rheumatic conditions, promoting collaboration and knowledge-sharing among professionals in the field.

ANAIS BRASILEIROS DE DERMATOLOGIA is a prestigious academic journal published by Elsevier Science Inc, specializing in the dynamic field of dermatology. With its Open Access model established in 2002, this journal ensures wide dissemination of research findings and facilitates collaboration within the dermatological community. Hailing from Brazil, it provides a platform for innovative research from both local and international contributors, spanning from its inception in 1963 to the current year, 2024. The journal positions itself as a vital resource in the dermatology sphere, currently ranked in the Q3 category for dermatology and holding a notable rank of 71 out of 142 in the Scopus rankings, placing it in the 50th percentile for its field. With a commitment to advancing knowledge and practice in dermatology, ANAIS BRASILEIROS DE DERMATOLOGIA is an essential read for researchers, professionals, and students eager to explore contemporary advancements and clinical practices.

AIMS Allergy and Immunology is a prestigious open access journal dedicated to advancing knowledge in the fields of allergy and immunology. Published by the American Institute of Mathematical Sciences (AIMS), this journal provides a vibrant platform for researchers, practitioners, and scholars to share groundbreaking findings and insights. Recognized for its commitment to disseminating high-quality research since its inception in 2017, AIMS Allergy and Immunology contributes significantly to the understanding of complex immunological mechanisms and allergic responses, thus playing a pivotal role in enhancing clinical practices and therapeutic strategies. With its ISSN 2575-615X, the journal aims to facilitate a robust exchange of ideas and promote collaboration within the scientific community. Researchers and practitioners are encouraged to access the latest studies and reviews, which are all freely available online, ensuring that vital information reaches a global audience without barriers. Together, we can tackle the challenges posed by allergies and immune disorders through rigorous scientific inquiry and innovation.